Oric Pharmaceuticals, Inc. - ORIC STOCK NEWS

ORIC Pharmaceuticals reported its financial results for Q2 2022, highlighting a robust cash position of $237.8 million to fund operations into the second half of 2024. The company is advancing three Phase 1 programs: ORIC-533 for multiple myeloma, ORIC-114 for EGFR/HER2 cancers, and ORIC-944 for prostate cancer, with initial data expected in 1H 2023. R&D expenses decreased to $13.8 million, while G&A expenses rose to $6.9 million. The CEO expressed confidence in their differentiated pipeline and upcoming clinical milestones.

ORIC Pharmaceuticals will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 8:00 a.m. ET. This clinical stage oncology company focuses on developing treatments targeting therapeutic resistance mechanisms. Key product candidates include ORIC-533 for multiple myeloma, ORIC-114 for genetically defined cancers, and ORIC-944 for prostate cancer. A live webcast of the event will be available on the company’s website, with a replay accessible for 90 days thereafter.

ORIC Pharmaceuticals, a clinical stage oncology company, announced that CFO Dominic Piscitelli will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET. The presentation will focus on the company's innovative treatment strategies for overcoming resistance in cancer therapies. It will be pre-recorded and accessible via their investor website, with a replay available for 90 days post-event. ORIC's pipeline includes ORIC-533, ORIC-114, and ORIC-944, targeting various cancers and mechanisms of resistance.

ORIC Pharmaceuticals reported Q1 2022 financial results, with cash and investments totaling $256.2 million, sufficient to fund operations into 2H 2024. The company is advancing three Phase 1b oncology programs, expecting initial data in 1H 2023 for ORIC-533, ORIC-114, and ORIC-944. Research and development expenses rose to $16.8 million due to the advancement of its product pipeline. General and administrative expenses increased to $6.4 million. The net loss for the quarter stood at $23.2 million, with net loss per share at $0.59.

ORIC Pharmaceuticals presented significant preclinical data at the 2022 AACR Annual Meeting, showcasing its broad oncology pipeline. ORIC-533, a CD73 inhibitor, showed potential in multiple myeloma, while ORIC-114 demonstrated efficacy against EGFR/HER2 mutations in advanced solid tumors. The company also introduced novel PLK4 inhibitors targeting breast cancer. Initial clinical data for ORIC-533, ORIC-114, and ORIC-944 is anticipated in the first half of 2023, emphasizing their potential in overcoming therapeutic resistance.

ORIC Pharmaceuticals announced the discontinuation of the development of ORIC-101 due to insufficient clinical activity in Phase 1b studies. The company will redirect efforts toward advancing three ongoing single-agent Phase 1 programs: ORIC-533 for multiple myeloma, ORIC-114 for EGFR/HER2 cancers, and ORIC-944 for prostate cancer. With a cash balance of $280.4 million, the cash runway is projected to extend into the second half of 2024. Initial data from the three programs is expected in the first half of 2023.

ORIC Pharmaceuticals (Nasdaq: ORIC) will host a conference call and webcast on March 21, 2022, at 5:00 p.m. ET to discuss its fourth quarter and full year 2021 financial results. The event will provide an operational update on the company's efforts to develop therapies addressing cancer treatment resistance, particularly their lead product candidate, ORIC-101, currently in Phase 1b trials. Participants can join via a domestic or international call or through their website, with a replay available for 90 days.

ORIC Pharmaceuticals announced a series of presentations at the 2022 AACR Annual Meeting from April 8-13, 2022, in New Orleans, LA. Key highlights include:

• ORIC-533, a CD73 inhibitor, demonstrated potential in reversing immunosuppression in multiple myeloma patients.
• ORIC-114 showcased superior brain penetration and anti-tumor activity in NSCLC models.
• New PLK4 inhibitors revealed promising results targeting synthetic lethality in breast cancer.

These presentations underscore ORIC's commitment to addressing therapeutic resistance in oncology.

ORIC Pharmaceuticals announced participation in a virtual fireside chat at the Guggenheim 2022 Oncology Conference on February 10, 2022, at 2:00 p.m. ET. The event will focus on the company’s innovations in overcoming cancer therapeutic resistance. Investors can access a live webcast through the company's website, with a replay available for 90 days. ORIC’s lead candidate, ORIC-101, targets glucocorticoid receptor resistance across solid tumors and is currently in Phase 1b trials for prostate cancer and other solid tumors.